Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

311 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Novel erythromycin derivatives with aryl groups tethered to the C-6 position are potent protein synthesis inhibitors and active against multidrug-resistant respiratory pathogens.
Ma Z, Clark RF, Brazzale A, Wang S, Rupp MJ, Li L, Griesgraber G, Zhang S, Yong H, Phan LT, Nemoto PA, Chu DT, Plattner JJ, Zhang X, Zhong P, Cao Z, Nilius AM, Shortridge VD, Flamm R, Mitten M, Meulbroek J, Ewing P, Alder J, Or YS. Ma Z, et al. Among authors: clark rf. J Med Chem. 2001 Nov 22;44(24):4137-56. doi: 10.1021/jm0102349. J Med Chem. 2001. PMID: 11708916
Discovery of ascomycin analogs with potent topical but weak systemic activity for treatment of inflammatory skin diseases.
Mollison KW, Fey TA, Gauvin DM, Sheets MP, Smith ML, Pong M, Krause R, Miller L, Or YS, Kawai M, Wagner R, Wiedeman PE, Clark RF, Gunawardana IW, Rhoades TA, Henry CL, Tu NP, BaMaung NY, Kopecka H, Liu L, Xie Q, Lane BC, Trevillyan JM, Marsh K, Luly JR, et al. Mollison KW, et al. Among authors: clark rf. Curr Pharm Des. 1998 Oct;4(5):367-79. Curr Pharm Des. 1998. PMID: 10197049 Review.
Novel inhibitors of bacterial protein synthesis: structure-activity relationships for 1,8-naphthyridine derivatives incorporating position 3 and 4 variants.
Clark RF, Wang S, Ma Z, Weitzberg M, Motter C, Tufano M, Wagner R, Gu YG, Dandliker PJ, Lerner CG, Chovan LE, Cai Y, Black-Schaefer CL, Lynch L, Kalvin D, Nilius AM, Pratt SD, Soni N, Zhang T, Zhang X, Beutel BA. Clark RF, et al. Bioorg Med Chem Lett. 2004 Jun 21;14(12):3299-302. doi: 10.1016/j.bmcl.2004.03.091. Bioorg Med Chem Lett. 2004. PMID: 15149694
Novel antibacterial class.
Dandliker PJ, Pratt SD, Nilius AM, Black-Schaefer C, Ruan X, Towne DL, Clark RF, Englund EE, Wagner R, Weitzberg M, Chovan LE, Hickman RK, Daly MM, Kakavas S, Zhong P, Cao Z, David CA, Xuei X, Lerner CG, Soni NB, Bui M, Shen LL, Cai Y, Merta PJ, Saiki AY, Beutel BA. Dandliker PJ, et al. Among authors: clark rf. Antimicrob Agents Chemother. 2003 Dec;47(12):3831-9. doi: 10.1128/AAC.47.12.3831-3839.2003. Antimicrob Agents Chemother. 2003. PMID: 14638491 Free PMC article.
Structure-activity relationships of novel potent MurF inhibitors.
Gu YG, Florjancic AS, Clark RF, Zhang T, Cooper CS, Anderson DD, Lerner CG, McCall JO, Cai Y, Black-Schaefer CL, Stamper GF, Hajduk PJ, Beutel BA. Gu YG, et al. Among authors: clark rf. Bioorg Med Chem Lett. 2004 Jan 5;14(1):267-70. doi: 10.1016/j.bmcl.2003.09.073. Bioorg Med Chem Lett. 2004. PMID: 14684340
311 results